Mar 5, 2018 · We analyzed the correlation between CDK7 and MYC mRNA levels in two clinical HCC cohorts (GSE14520 n = 225 and TCGA database n = 371).

In the present study, we demonstrated that HCC cells were highly susceptible to THZ1, a selective covalent CDK7 inhibitor. We further discovered that transcription factor MYC-promoted cell proliferation renders cancer cells hypersensitive to apoptotic cell death with THZ1 treatment.

By analysis of TCGA data and clinical specimens, we demonstrated that BRD4 and CDK7 were frequently overexpressed in human HCCs and were associated with the poor prognosis. Shorter survival and poorly differentiated histology were linked to high BRD4 or CDK7 expression levels.

Conclusions: The CDK7 expression level in HCC is associated with HCC progression, prognosis and the cell proliferation capacity. CDK7 may act as a potential target for HCC, and THZ1 might be a potent medicine for HCC treatment.

Sep 15, 2018 · Mechanistically, CDK7 interacted with beta-catenin, enhanced the interaction between beta-catenin and TCF4, and activated beta-catenin/TCF signaling. Taken together, this study demonstrated the oncogenic roles of CDK7 in HCC and suggested that CDK7 might be a promising therapeutic target.

Mar 28, 2022 · The inhibition of cyclin-dependent kinase 7 (CDK7) activity has shown therapeutic efficacy in HCC. However, the underlying molecular mechanisms remain elusive. Here, we show that three HCC lines, HepG2, Hep3B, and SK-Hep-1, …

Affiliations 1 Division of Molecular Carcinogenesis, Oncode Institute, Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; 2 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School …

now identifies CDK7 inhibition as vulnerability of HCC tumors having high MYC expression. The recent start of a clinical study with a CDK7 inhibitor (NCT03134638) may enable clinical

Jan 30, 2024 · Our study suggested that BRD4 and CDK7 coupled can be a valuable biomarker in HCC diagnosis and the combination of JQ1 and THZ1 can be a promising therapeutic treatment against HCC.

Two previous studies have shown that MYC proteins are potential biomarkers of response to CDK7 inhibitors in small cell lung cancer and neuroblastoma. 8,9 Our work now identifies CDK7 inhibition as vulnerability of HCC tumors having high MYC expression.